Literature DB >> 26820260

High Prevalence and Incidence of HIV and HCV Among New Injecting Drug Users With a Large Proportion of Migrants--Is Prevention Failing?

Cinta Folch1,2,3, Jordi Casabona1,2,3,4, Albert Espelt2,5,6, Xavier Majó7, Mercè Meroño8, Victoria Gonzalez1,2,9, Lucas Wiessing10, Joan Colom7, M Teresa Brugal2,5.   

Abstract

OBJECTIVES: The aim of this study was to assess differences in the prevalence of HIV and HCV infection and associated risk factors between new (injecting for ≤5 years) and long-term injectors and to estimate HIV/HCV incidence among new injectors.
METHODS: Cross-sectional study among people who inject drugs (PWID) who attended harm reduction centers in Catalonia in 2010-11. Anonymous questionnaires and oral fluid samples were collected. Poisson regression models were applied to determine the association between HIV/HCV infection and risk factors.
RESULTS: Of the 761 participants, 21.4% were new injectors. New injectors were younger than long-term injectors (mean age = 31.6 vs. 37.8) and were more likely to be immigrants (59.0% vs. 33.4%). HIV and HCV prevalence was 20.6% and 59.4% among new injectors, and estimated HIV and HCV incidence 8.7 and 25.1 /100 person-years, respectively. Among new injectors, HIV infection was associated with homelessness (PR = 3.10) and reporting a previous sexually transmitted infection (PR = 1.79). Reporting front/backloading (PR = 1.33) and daily injection (PR = 1.35) were risk-factors for HCV infection. For long-term injectors, HIV risk factors were: having shared syringes (PR = 1.85), having injected cocaine (PR = 1.38), reporting front/backloading (PR = 1.30) and ever having been in prison (PR = 2.03).
CONCLUSION: A large proportion of PWID in Catalonia are new injectors, a subgroup with a high level of both sexual and parenteral exposure and a high incidence rate of HIV/ HCV infections. It is important to improve early diagnosis of these infections among this group, in particular among migrants. To identify and address risk factors for homelessness PWID should be a priority.

Entities:  

Keywords:  HIV, injecting drug use; Hepatitis C; migrants; new injectors

Mesh:

Year:  2016        PMID: 26820260     DOI: 10.3109/10826084.2015.1092991

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  20 in total

1.  Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine.

Authors:  Olena Iakunchykova; Anna Meteliuk; Alexei Zelenev; Alyona Mazhnaya; Melissa Tracy; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2018-04-12

Review 2.  Injection Drug Use Trajectories among Migrant Populations: A Narrative Review.

Authors:  Jason S Melo; Maria Luisa Mittal; Danielle Horyniak; Steffanie A Strathdee; Dan Werb
Journal:  Subst Use Misuse       Date:  2018-01-24       Impact factor: 2.164

Review 3.  HIV outcomes among migrants from low-income and middle-income countries living in high-income countries: a review of recent evidence.

Authors:  Jonathan Ross; Chinazo O Cunningham; David B Hanna
Journal:  Curr Opin Infect Dis       Date:  2018-02       Impact factor: 4.915

4.  Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.

Authors:  Andreea A Artenie; Evan B Cunningham; Gregory J Dore; Brian Conway; Olav Dalgard; Jeff Powis; Philip Bruggmann; Margaret Hellard; Curtis Cooper; Philip Read; Jordan J Feld; Behzad Hajarizadeh; Janaki Amin; Karine Lacombe; Catherine Stedman; Alain H Litwin; Pip Marks; Gail V Matthews; Sophie Quiene; Amanda Erratt; Julie Bruneau; Jason Grebely
Journal:  Clin Infect Dis       Date:  2020-05-23       Impact factor: 9.079

5.  Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?

Authors:  Dimitra Panagiotoglou; Emanuel Krebs; Jeong Eun Min; Michelle Olding; Keith Ahamad; Lianping Ti; Julio S G Montaner; Bohdan Nosyk
Journal:  Int J Drug Policy       Date:  2017-06-01

6.  Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study.

Authors:  Yin Liu; Yu Liu; Xia Zou; Wen Chen; Li Ling
Journal:  BMJ Open       Date:  2017-07-13       Impact factor: 2.692

7.  Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities.

Authors:  Micah Oyaro; John Wylie; Chien-Yu Chen; Raphael O Ondondo; Anna Kramvis
Journal:  South Afr J HIV Med       Date:  2018-03-27       Impact factor: 2.744

8.  Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.

Authors:  César Garriga; Sandra Manzanares-Laya; Patricia García de Olalla; Pilar Gorrindo; Sabela Lens; Ricard Solà; María Martínez-Rebollar; Montserrat Laguno; Jordi Navarro; Xavier Torras; Mercè Gurguí; María-Jesús Barberá; Josep Quer; Eva Masdeu; Pere Simón; Miriam Ros; Anna de Andrés; Joan A Caylà
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

9.  Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.

Authors:  Lucas Wiessing; Marica Ferri; Vendula Běláčková; Patrizia Carrieri; Samuel R Friedman; Cinta Folch; Kate Dolan; Brian Galvin; Peter Vickerman; Jeffrey V Lazarus; Viktor Mravčík; Mirjam Kretzschmar; Vana Sypsa; Ana Sarasa-Renedo; Anneli Uusküla; Dimitrios Paraskevis; Luis Mendão; Diana Rossi; Nadine van Gelder; Luke Mitcheson; Letizia Paoli; Cristina Diaz Gomez; Maitena Milhet; Nicoleta Dascalu; Jonathan Knight; Gordon Hay; Eleni Kalamara; Roland Simon; Catherine Comiskey; Carla Rossi; Paul Griffiths
Journal:  Harm Reduct J       Date:  2017-04-22

10.  Concordance between self-reported and measured HIV and hepatitis C virus infection status among people who inject drugs in Germany.

Authors:  Stine Nielsen; Martyna Gassowski; Benjamin Wenz; Norbert Bannert; Claus-Thomas Bock; Claudia Kücherer; R Stefan Ross; Viviane Bremer; Ulrich Marcus; Ruth Zimmermann
Journal:  Hepatol Med Policy       Date:  2016-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.